OBJECTIVES: Adults with failing Fontan circulation (FFC) represent a heterogeneous, high-risk group for cardiac transplantation with poor reported outcomes. We studied the impact of mode of Fontan failure ( preserved versus impaired systolic ventricular function) and endorgan dysfunction on early survival in adults undergoing cardiac transplantation for FFC.
INTRODUCTION
Implementation of the Fontan principle has resulted in excellent palliation for a wide variety of single-ventricle anatomies and physiologies [1] . It has recently become evident, however, that important conditional attrition in early survivors occurs from beyond 15-20 years following Fontan palliation [2, 3] . Bringing the systemic and pulmonary vascular beds in direct series, therefore, appears to exhibit an unnatural history with a certain time-related inevitability of failure [4] . This is of concern as it appears the adult single-ventricle population presenting with Fontan failure is growing [2, 5] . Thus, increasing numbers of end-stage failing Fontan patients are presenting for cardiac transplantation. Many have important end-organ dysfunction (EOD) and only select few are suitable for conversion or short-term mechanical assistance [6] [7] [8] [9] . While outcomes for heart transplantation for Fontan failure are now excellent in the paediatric population [8, 10, 11] , outcomes in adults have been reported as relatively poor, with largely undefined risk factors for mortality [12, 13] . Importantly, the major determinants of morbidity and mortality in FFCs appear to be different in paediatric and adult populations [12] [13] [14] .
Two distinct modes of Fontan failure have been proposed: preserved versus impaired systolic ventricular function (PVF versus IVF) [12, 15, 16] . Those with PVF may be at increased risk following cardiac transplantation [15, 16] . Why certain patients with FFC exhibit PVF, however, is not clear. The failing Fontan state is also characterized by systemic venous hypertension with elevated post-sinusoidal pressure in the liver and portal hypertension. Widespread multisystem dysregulatory sequelae then ensue, including portal fibrosis, ascites, splenomegaly, varices, autonomic dysfunction with systemic vasodilatation and extracellular fluid retention; renal failure may occur due to reduced renal blood flow and systemic venous congestion [17] . One may thus consider a hepato-centric model for much of the subsequent EOD in late adult Fontan failure. Non-invasive liver imaging, VAST score (reflecting portal hypertension: varices, ascites, splenomegaly, thrombocytopaenia) and biochemical markers are useful in quantifying EOD [17] [18] [19] [20] ; serum albumin in particular is often decreased in patients with FFC, notably those with PVF [15, 16, 21, 22] .
We wished to study our 26-year experience of cardiac transplantation in adults with FFC and asked whether one can riskstratify these patients. We examined what may have driven any observed improvement in survival and the impact of mode of failure and EOD on outcomes.
PATIENTS AND METHODS

Patient demographics and study design
This was a retrospective review of all adult (≥16 years) Fontan patients who underwent cardiac transplantation at our institution from 1990 to 2015. All variants of the Fontan procedure were included. Single-ventricle physiology patients with no prior interventions or who had not undergone Fontan completion were excluded. Institutional ethics approval was waived on the basis of this being a retrospective study representing an extension of our previously approved study [7] . As a quaternary referral centre in the North-East of the UK, Freeman Hospital undertakes the majority of complex adult congenital heart transplants within the UK. Of the patients in this study, 6 were from our own region, with 20 referred from 10 different specialist centres outside Newcastle. As such, we believe this cohort represents almost the entire UK experience of adult failing Fontan cardiac transplants. Follow-up was complete in all patients up until January 2016.
Patients were defined as failing Fontans based on functional criteria (New York Heart Association status; NYHA III-IV) as well as haemodynamic and phenotypic evidence of FFC: impaired systolic and/or diastolic ventricular function on echocardiography; elevated mean pulmonary artery pressures (MPAP) or systemic ventricular end-diastolic pressure (SVEDP) on cardiac catheter; the presence of persistent severe pleural effusions/ascites, proteinlosing enteropathy (PLE) or plastic bronchitis (PB) [17] . Patients with PVF were defined as having no more than mild reduction in ejection fraction [15, 16] . Criteria for mild, moderate or severe impairment of systolic function were ejection fractions of 45-54, 30-44 and <30%, respectively, according to the European Society of Cardiology/American Society of Echocardiography guidelines 2005.
Assessment of EOD focused on hepato-renal dysfunction. The MELD-XI score (Model for End-stage Liver Disease eXcluding INR) takes into account serum creatinine and bilirubin; this modified score was employed as many of the patients were taking warfarin [19] . Patients also underwent ultrasound (USS) imaging of their liver with the USS-based liver changes scored semi-quantitatively from 0 to 3 based on no/mild-moderate-severe changes of fibrosis or frank cirrhosis. In addition, patients were assessed for features of portal hypertension using the VAST score [20] . PLE was defined by symptoms and alpha-1 antitrypsin levels [21] . The primary outcome of interest was survival; secondary outcomes were major morbidity, including need for mechanical circulatory support (MCS).
Anaesthesia, surgery and perioperative management
Computed tomography scan and vascular USS were performed to assess detailed cardiac anatomy and patency of neck and femoral arteries and veins as well as the inferior vena cava. Some patients were admitted to our institution for intravenous inotrope and diuretic therapy prior to transplant for preoptimization. Patients received individualized antibiotic prophylaxis based on local institutional guidance. Aprotinin was administered prior to surgery.
Principles of operative strategy involved appropriate reconstructive techniques for pulmonary arteries and systemic venous drainage with bicaval anastomosis in all cases, as we have previously described [6] . An important aspect was the co-ordination between donor and recipient teams to minimize organ ischaemic times as well as achieving safe sternal re-entry with completion of preliminary dissection prior to the administration of systemic heparin and institution of cardiopulmonary bypass (CPB). Donor hearts were oversized to maximize the ability of the transplanted organ to function in a setting of likely increased pulmonary vascular resistance [11] .
Management of patients on extracorporeal circulation on account of the high collateral circulation in failing Fontan patients importantly comprised maintenance of adequate mean systemic arterial pressure using 'super-flow' of 125% of normal (cardiac index 2.4 l/min/m 2 ) in conjunction with vasoconstrictor medication; typically, a tonic infusion of vasopressin at 1-2 units/h. Modified ultrafiltration at cessation of CPB ensured a haematocrit of >40.
While all patients were weaned from CPB with inhaled nitric oxide and had had a patent foramen ovale created, we realized the importance of maintaining pulmonary vasodilators in the early postoperative period in the form of isoprenaline and, more recently, inhaled epoprostenol to minimize risks of acute right ventricle-pulmonary artery uncoupling and RV failure [11] . This has enabled earlier extubation of patients while reducing the afterload on the highly susceptible right ventricle of the newly transplanted heart. All patients received a vascular haemodialysis catheter in the operating room due to the anticipated need for renal replacement therapy (RRT). Immunosuppression regimen was as previously reported by our institution [7] .
Statistical analysis
Continuous data were reported as mean ± standard deviation (SD) or as medians with the stated range. Comparison of means was performed using the unpaired t-test without assuming equality of variances (Levene's test). Comparisons for variables with multiple ordinal or nominal scores were performed using the nonparametric, Kruskal-Wallis test; binomial data were expressed as proportions and comparative univariate analysis performed using Fisher's exact test. Kaplan-Meier analysis was used for survival with the log-rank test used to determine significant differences. Two covariates (PVF and heterotaxy; both with P < 0.05 on univariate analysis) were entered into the Cox multivariable regression model to determine independent predictors for mortality. A probability value of <0.05 was taken to represent a statistically significant difference between groups. Analyses were performed using IBM Statistical Package for the Social Sciences (SPSS) version 22 (SPSS Inc., Chicago, IL).
RESULTS
Study cohort and characteristics
A total of 26 patients transplanted over the period of this study were included. The mean age at transplantation of patients in the study was 26.1 ± 8.6 years, with a mean listing transplant waiting time of 128.6 ± 159.6 days. Mean age at initial Fontan surgery was 8.6 ± 5.7 years, with a mean Fontan Transplant Interval (FTI) of 17.7 ± 9.1 years. The majority of patients with single-ventricle anatomy had systemic left ventricles. Tricuspid atresia (TA) and double inlet left ventricle (DILV) represented the most common underlying diagnoses (61% of total; Fig. 1 ). All patients had undergone at least one surgical procedure prior to Fontan (range: 1-8 procedures). Thirteen patients had prior extracardiac conduit Fontan, 7 had atriopulmonary connections or Bjork's modification, 4 lateral tunnels and 2 modified Fontans. Three patients had originally received fenestrated Fontan connections; 4 patients had undergone Fontan conversion. There were 7 heterotaxy patients and 3 patients with PLE, though none with PB. All 3 patients with PLE had PVF. Eleven patients in total had failed Fontan physiology with PVF as the primary mode of failure. Concerning the assessment of EOD, mean MELD-XI at transplant score was 14.2 ± 5.8; median VAST score was 1. Six patients had >Grade 2 changes on liver USS imaging. Two IVF patients did not have data for both USS and VAST scores. Mean CPB time was 277.0 ± 165.2 min, with mean total donor ischaemic time (IT) of 187.6 ± 58.7 min. A single patient in our series underwent combined heart-liver transplantation.
Overall survival and major morbidity
Median follow-up was 2.1 years (range 0-20.2). Overall 30-day survival rate for our entire cohort was 69.2%. Considering two equal 13-year eras between 1990 and 2015, three deaths occurred within 1 week of surgery, all from the first era (2/5 = 40% 30-day survival). For the second era, 30-day survival rate had improved to 76.2% (16/21 patients). Over the period of this study, 62 adult non-Fontan congenital patients were transplanted. Actuarial survival for these patients was similar to that for adult failing Fontan patients ( Fig. 2 ; P = 0.82). The single heart-liver recipient is alive and well at 277 days. The three immediate deaths in our initial experience were all attributable to overwhelming bleeding with gross haemodynamic instability in the critical reperfusion phase with subsequent graft dysfunction and multi-organ failure (MOF) with vascular, hepatic, renal and gut insufficiency. These represented the learning curve in surmounting this first barrier, 2 of the 3 patients requiring emergent peripheral femoral artery cannulation for CPB. These patients did not survive long enough to accrue further complications. Four patients required MCS, 13 required RRT, 2 experienced cerebrovascular accidents (CVAs) or seizures; 4 patients had major sepsis; 2 patients had ischaemic lower limb complications. The incidence of these complications, however, was not different on univariate comparison, either according to survival status or mode of failure. Only MOF/gut failure and major bleeding occurred more frequently in non-survivors (P < 0.05 for both).
Factors influencing survival: ventricular function and end-organ dysfunction
In comparing survivors with non-survivors, there were no significant differences in gender, age at Fontan, age at transplant or FTI ( Table 1) . The proportions of patients in sinus rhythm were also similar in the two groups, as was the median number of prior surgeries. All patients in the two groups had similarly low measured transpulmonary gradient (TPG). The mean panel reactive antibody (PRA) level and degree of atrioventricular valve (AVV) regurgitation were also similar among survivors and those who had died ( Table 1) . Of the peritransplant variables, the donor:recipient weight ratio, CPB and total IT did not differ significantly between the two groups ( Table 1) . MPAP and SVEDP were somewhat elevated, though to similar extents in survivors and non-survivors. Importantly, there were significantly greater proportions of patients with PVF and heterotaxy among those who died (P = 0.01; P = 0.03, respectively; Table 1 ). Actuarial survival was also significantly worse in PVF versus IVF and in heterotaxy+ versus heterotaxy groups (log-rank; P = 0.01 for both; Fig. 3A and B) . We also noted higher mean MELD-XI scores at transplant in patients who died compared with survivors (16.9 ± 8.2 vs 13.0 ± 4.0; P = 0.01; Table 1 ). The MELD-XI score in itself, however, was not a good predictor of mortality with an unsatisfactory receiver operating characteristic (ROC) curve (area under curve = 0.647; P = 0.24; data not shown).
Cox multivariable regression confirmed PVF as a significant independent risk factor for death (OR 5.38; CI 1.08-26.96; P = 0.04; Table 2 ). While liver USS score, VAST score and serum albumin were not dissimilar among survivors and those who died, this was not the case when examining the PVF subset of patients. Comparing PVF versus IVF patients, CPB and ischaemic times were similar, as was the FTI for the two groups ( Table 3) . The proportion of patients with heterotaxy was also similar. Although the MELD-XI score was greater in PVF patients, this difference was not significant. We did, however, observe significantly higher liver USS and VAST scores in PVF patients (Table 3) . Further, PVF patients exhibited significantly lower serum albumin levels than IVF patients did ( Fig. 4A ; P = 0.01). A trend towards lower serum albumin with increasing SVEDP was also observed, and this was more pronounced in PVF patients (Fig. 4B) . Four patients had PVF and survived. Of these, 3 had elevated VAST scores of 3-4 (including the single heart-liver patient); 1 patient had a normal VAST score (Table 4) .
DISCUSSION
We have presented the largest single-centre experience of cardiac transplantation in adults with Fontan failure. We observed comparable outcomes for survival in adult failing Fontan patients versus adult non-Fontan congenital transplant recipients. Preserved ventricular function was a significant independent predictor of mortality on multivariable analysis. PVF patients, in turn, exhibited more extensive structural liver changes on USS as well as higher VAST scores indicative of portal hypertension and lower serum albumin levels.
Survival
Our observed 69.2% early survival compares favourably with the 50% survival (4/8 patients) in adults ≥16 years reported by Backer et al., and the 38.9% survival (7/18) in the series by Davies et al. [12, 13] . Improving outcomes were achieved in our series between the first and second eras, with an almost 2-fold improvement in 30-day survival (76.2 vs 40%). We believe that this improvement in outcomes may have been driven by several factors: techniques for safe sternal re-entry and dissection prior to heparin administration; minimizing of donor heart ischaemic times; super flow on CPB with tonic dose vasopressors to maintain adequate perfusion, in particular of the gut and liver. Importantly, strategies to minimize right ventricle-pulmonary artery uncoupling and subsequent RV failure post-transplant may have played a key role [11] . These strategies included oversizing of donor hearts and routine use of isoprenaline and inhaled nitric oxide and nebulized epoprostenol perioperatively. Although patients in our series did not exhibit elevated MPAP pretransplant, we assumed all recipients to have elevated PVR as measurements of PVR in the failing Fontan circulation are recognized to be underestimates in the setting of significant aortopulmonary collaterals (APCs), non-pulsatile flow through the pulmonary vascular bed and impaired cardiac function [4, 11, 17] . Our strategy for transplanting adults with FFC has evolved over time, and we believe that our overall present model of care for 47.4 ± 6.7 36.6 ± 9.8 0.01* Liver USS category these patients has been an additional important driver for the improving outcomes reported here. This model consists of a single congenital team managing all aspects of assessment, listing, optimization, transplant and perioperative care with a large combined experience of both adult and paediatric congenital cardiac transplantation (Fontan and non-Fontan) .
Morbidity
In the present series, major morbidity included the need for MCS, MOF/gut ischaemia, need for RRT, sepsis, bleeding, CVA/seizures and lower limb ischaemia. It was not possible, however, to discern an association between major morbidity and mode of Fontan failure, MELD-XI, liver USS or VAST scores, nor with the use of perioperative vasopressor agents. Importantly, neither of the 2 patients with lower limb ischaemia had undergone CPB via the femoral artery.
We have yet to evolve better techniques for assessing perioperative gut, liver or limb perfusion or means to better prevent peritransplant insult to these organ systems. In terms of predictors of mortality, other investigators have reported infection and sepsis as the major cause of demise following the immediate peritransplant period in adults with FFC [12, 13] . We did not observe this in our patient cohort. Whether this relates to a less aggressive immunosuppression protocol is not clear, though we did not observe a higher incidence of rejection compared with other series [13] .
End-organ hepatic dysfunction
Structural liver changes occur in the majority of Fontan patients [17] . Elder et al. [20] found that Fontan patients with significant portal hypertension (reflected by a VAST score of ≥2), a consequence of severe Fontan-associated liver disease, had a 9-fold increased risk of death or major adverse cardiovascular events compared with those with VAST score <2. Although VAST scores were similar in our study between survivors and non-survivors, we noted that median liver USS and VAST scores were both significantly higher in PVF patients compared with IVF ones (Table 3) . There were most deaths in patients with both PVF and liver USS or VAST scores ≥2 (Table 4) . Aside from the single heart-liver recipient with PVF who survived, it is not clear what favoured survival in the 3 other PVF survivors; 2 had VAST scores 3-4. Certainly threefourth of these PVF+ survivors received pretransplant intravenous inotropes and diuretics. With the exception of these 3 patients, no other clear association was found between attempts at preoptimization and survival or freedom from major morbidity in our cohort.
Preserved ventricular function
PVF emerged as a significant independent predictor of mortality. Several studies have suggested that patients with PVF may be at increased risk following cardiac transplant [8, 15, 16] . PVF patients have primarily diastolic dysfunction which is a well-described phenomenon late after Fontan [23] . Thresholds for significant elevation of SVEDP have been defined as >10-12 mmHg [24] , and the mean SVEDP of 13.8 ± 5.2 we observed in PVF patients is in the range reported by other investigators for adults with FFC and PVF [8, [15] [16] [17] . Patients with PVF have been noted to have higher PVR, lower SVR, a greater incidence of APCs and lower serum albumin [15, 16] . Interestingly, we observed a trend towards lower serum albumin with increasing SVEDP in PVF patients. Recent work by Yoo et al. [22] in young adults with Fontan circulation showed an inverse correlation between serum albumin and increasing liver stiffness as measured by transient elastography. Thorne et al. [21] found elevated GI protein loss associated with increasing systemic venous pressure in Fontan patients, many with PVF. It may therefore be possible that FFC with PVF reflects a state with a more perturbed Fontan pathophysiology (high PVR, low SVR, high SVEDP, more APCs), with greater EOD (more structural liver changes, portal hypertension, lower albumin) and that this translates into a higher risk for cardiac transplantation.
As to why some patients with FFC exhibit PVF remains unclear. One might postulate a greater degree of ventriculoarterial uncoupling as the primary driver. In this regard, greater arterial impedance could result in a relatively higher degree of systemic ventricular hypertrophy and fibrosis with more marked diastolic impairment with consequent preserved systolic function, though with increased PVR and systemic venous hypertension. This hypothesis may be supported by recent data from Ozawa et al. [25] , who demonstrated increased systemic ventriculoarterial uncoupling with increased contractility-afterload mismatch in Fontan patients with lower serum albumin and PLE. There was no difference in arterial elastance (Ea) or Ea/end-systolic elastance (Ees) ratio in PLE versus non-PLE patients prior to Fontan completion. Of note, there was an increasing Ea/Ees ratio over time in PLE patients from early after Fontan surgery, well before the subsequent onset of PLE [25] . This suggests that the lower albumin group represents a distinct subset of patients in terms of their Fontan pathophysiology as implied by our finding of lower serum albumin and higher liver USS and VAST scores at transplant in those with PVF.
Study limitations
This was a retrospective, single-centre study. Our sample size was therefore limited and inferences drawn from the present data should be validated in future larger, multicentre studies. Our assessment protocol for adult failing Fontan patients continues to evolve and only recently has included more detailed cross-sectional liver imaging and non-invasive elastography measurements [18] , and future prospective studies may enable earlier detection of Fontan-associated liver dysfunction using these methodologies, with the prospect for improving cardiac transplant outcomes.
CONCLUSIONS
Favourable outcomes may be achieved in adults with failing Fontan circulation undergoing cardiac transplantation. Our model of a dedicated single congenital team dealing with all adult and paediatric cardiac transplants from the point of assessment and listing through to transplant may have positively influenced outcomes at our institution. We suggest that outcomes even in patients with PVF may continue to improve with evolving methods for assessment and preoptimization. Further, many adult failing Fontan patients are smaller in size and may have a privileged position in terms of availability of adequate sized organs. We therefore believe that the problem of organ allocation and competition may not be as acute as one perceives and that one should not presently preclude any adult failing Fontan patient from formal cardiac transplant assessment whilst data from larger, prospective multicentre studies are awaited.
